Cancer Stem Cell News Volume 10.22 | Jun 9 2021

    By
    Justin.choi
    -
    0
    217






    2021-06-09 | CSCN 10.22


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.22 – 9 June, 2021
    TOP STORY

    Predicting Metastasis from Cues of Metastatic Cancer Stem-Like Cells-3D-Ultrasensitive Metasensor at a Single-Cell Level
    Scientists generated an ultrasensitive 3D-metasensor to efficiently capture and investigate metastatic CSCs and magnified the vital premetastatic signals from a single cell.
    [ACS Nano]
    AbstractGraphical Abstract
    Tumors Are 3D. Shouldn't Your In Vitro Model Be? Learn More.
    PUBLICATIONSRanked by the impact factor of the journal

    High-Fat Diet-Activated Fatty Acid Oxidation Mediates Intestinal Stemness and Tumorigenicity
    The authors proposed that a high-fat diet enhanced intestinal stemness and tumorigenicity by engaging a peroxisome proliferator-activated receptor-fatty acid oxidation program.
    [Cell Reports]
    Full Article

    αSMA+ Fibroblasts Suppress Lgr5+ Cancer Stem Cells and Restrain Colorectal Cancer Progression
    Scientists demonstrated that αSMA+ cancer-associated fibroblast in colorectal cancer (CRC) exerted tumor-restraining functions via BMP4/TGFβ1 paracrine signaling that served to suppress Lgr5+ CSCs and promoted anti-tumor immunity, ultimately limiting CRC progression.
    [Oncogene]
    Abstract

    RAL GTPases Mediate EGFR-Driven Intestinal Stem Cell Proliferation and Tumorigenesis
    In addition to impacting stem cell proliferation during damage-induced intestinal regeneration, the role of RAL GTPases impacted EGFR-dependent tumorigenic growth in the intestine and in the human mammary epithelium.
    [eLife]
    Abstract

    The PI3K/mTOR Inhibitor Gedatolisib Eliminates Dormant Breast Cancer Cells in Organotypic Culture, but Fails to Prevent Metastasis in Preclinical Settings
    By probing a number of kinases downstream of integrin-β1, researchers determined that PI3K inhibition with either a tool compound or a compound in clinical trials robustly sensitized quiescent breast tumor cells seeded in organotypic bone marrow cultures to chemotherapy.
    [Molecular Oncology]
    AbstractFull Article

    Altered Lipid Metabolism Marks Glioblastoma Stem and Non-Stem Cells in Separate Tumor Niches
    Investigators interrogated gene expression in separate microenvironments of glioblastoma organoid models that mimicked the transition between nutrient-rich and nutrient-poor pseudopalisading/perinecrotic tumor zones using spatial-capture RNA-sequencing.
    [Acta Neuropathologica Communications]
    Full Article

    Activation of Wnt Signaling Reduces the Population of Cancer Stem Cells in Ameloblastoma
    The authors identified a putative CSC population in immortalized and primary human ameloblastoma cells and examined possible therapeutic reagents to reduce the CSC population.
    [Cell Proliferation]
    Full Article

    Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma
    Investigators suggested that combined treatment with the DRD2/3 antagonist ONC201 and radiation improved the efficacy of radiation against glioblastoma (GBM) in vitro and in vivo through suppression of glioma-initiating cells without increasing toxicity in mouse models of GBM.
    [Radiotherapy and Oncology]
    AbstractGraphical Abstract

    RAD51AP1 Loss Attenuates Colorectal Cancer Stem Cell Renewal and Sensitizes to Chemotherapy
    Researchers provided in vivo evidence that RAD51-Associated Protein 1(RAD51AP1) played a critical role in colorectal cancer (CRC) growth and drug resistance by regulating CRC stem cell self-renewal.
    [Molecular Cancer Research]
    Abstract

    Identification of Cancer Cell Stemness-Associated Long Noncoding RNAs for Predicting Prognosis of Patients with Hepatocellular Carcinoma
    Cancer cell stemness-associated lncRNAs and their relevance in the prediction of clinical prognosis remain largely unexplored. Through the transcriptome-wide screen, scientists identified a total of 136 liver CSC-associated lncRNAs.
    [DNA and Cell Biology]
    Abstract

    New human primary cancer-sourced blood products, immune cell subsets, and more. Click to view products.
    REVIEWS

    Cancer Stem Cell–Immune Cell Crosstalk in Tumor Progression
    The authors discuss the signaling programs that simultaneously induce CSCs and reprogram the immune response to facilitate tumor immune evasion, metastasis, and recurrence.
    [Nature Reviews Cancer]
    Abstract

    Tissue Mechanics in Stem Cell Fate, Development, and Cancer
    Scientists review how dysregulation of tissue-level force increases the risk of malignancy, promotes tumor progression, and can induce a stem-like phenotype in tumor cells to drive tumor aggression and treatment resistance.
    [Developmental Cell]
    Full Article
    INDUSTRY AND POLICY NEWS

    bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
    bluebird bio, Inc. announced that the FDA has lifted the clinical holds on the Phase I/II HGB-206 and Phase III HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 and Northstar-3 studies of betibeglogene autotemcel gene therapy for adult, adolescent and pediatric patients with transfusion-dependent β-thalassemia.
    [bluebird bio, Inc.]
    Press Release
    FEATURED EVENT

    EMBO Workshop: Cell Size and Growth Regulation
    June 21 – 24, 2021
    Virtual

    > See All Events
    JOB OPPORTUNITIES

    Postdoctoral Fellow – Precision Oncology of Gastrointestinal Cancers
    City of Hope – CMonrovia, California, United States

    Research Technologist – Neurological Surgery
    Northwestern University – Chicago, Illinois, United States

    Postdoctoral Positions – Hematopoiesis and Leukemia
    UT Southwestern Medical Center – Dallas, Texas, United Statess

    Director – The Roslin Institute
    The University of Edinburgh – Edinburgh, Scotland, United Kingdom

    Postdoctoral Position – Stemness Control in Pluripotent and Cancer Cells
    Columbia University Medical Center – New York, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter